# Heidelberg Innovation

> Heidelberg Innovation is a VC fund in Heidelberg backing Biotechnology and Pharmaceutical. See 4 investments, round sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Heidelberg, Germany
- Total investments: 4
- Last investment: May 2014
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/heidelberg-innovation/
- Website: http://www.hd-innovation.de/en/company/ueber_uns

Heidelberg Innovation is a German investment company catering to life sciences companies with a focus on medical technology.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 100% |
| Pharmaceutical | 3 | 75% |
| Medical | 2 | 50% |
| Health Care | 2 | 50% |
| Biopharma | 1 | 25% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 3 | 75% |
| Funding Round | 1 | 25% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Germany | 2 | 50% |
| Switzerland | 1 | 25% |
| United States | 1 | 25% |

## Investments

| Company | Description | Round size | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Lophius Biosciences | Lophius Biosciences is a young biotechnology company developing innovative products for the diagnosis of acute infectious and autoimmune diseases. The company is also offering custom-made services in the area of cell based bioactivity and quality tests for pharmaceutical agents. The core competencies of Lophius Biosciences are in the area ofImmunology and T-cell diagnostics.Lophius Biosciences is a privately-held German biotechnology company focusing on the development and marketing of innovative immune diagnostic systems to improve therapy control and personalized treatment of patients in the area of transplantation, infectious and autoimmune diseases.The company’s developments are based on its expertise in cell-mediated immunity as well as on its proprietary T-activation® and Reverse T Cell Technology platforms. Whereas the T-activation® technology platform allows an efficient stimulation of a broad spectrum of clinically-relevant immune effector cells to accurately measure the cell-mediated immunity, the Reverse T Cell Technology platform can distinguish between active and memory T cells to develop innovative diagnostics. | $2.2M |  | May 08, 2014 |  |
| Santhera Pharmaceuticals | Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focusing on the development and marketing of innovative pharmaceutical products for the treatment of mitochondrial and neuromuscular diseases. This area of high unmet medical need includes many orphan and niche indications with no current therapy. | $17.6M | Series B | Dec 20, 2005 |  |
| Alantos Pharmaceuticals | Alantos Pharmaceuticals is a chemistry-driven biopharmaceutical company. It engages in the discovery and development of small molecule drugs for osteoarthritis, inflammation, and type II diabetes. Their products include Dipeptidyl and Peptidase IV inhibitor. The company offers various tissue remodeling pathways for rheumatoid arthritis, liverfibrosis, cardiovascular, chronic wound healing, and cancer. Alantos Pharmaceuticals was founded in 2002 and is based in Cambridge, Massachusetts. |  | Series B | Mar 10, 2005 |  |
| CellZome | CellZome is a pharmaceutical company that discovers, develops, and commercializes kinase-targeted drugs for the treatment of inflammatory diseases. It develops a pipeline of kinase inhibitors targeting inflammatory mediators as oral therapeutics for rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, psoriasis, and asthma.CellZome was founded in 2000 and is based in Heidelberg, Baden-Wurttemberg. | $31M | Series B | Mar 01, 2001 |  |

4 of 4 investments shown.

## Co-investors
- [Oxford Bioscience Partners](https://shizune.co/investors/profile/oxford-bioscience-partners) — VC Fund, 2 deals together
- [3i Group](https://shizune.co/investors/profile/3i-group) — VC Fund, 1 deal together
- [ABN AMRO Fund](https://shizune.co/investors/profile/abn-amro) — VC Fund, 1 deal together
- [Advent International](https://shizune.co/investors/profile/advent-international) — VC Fund, 1 deal together
- [Atlas Venture](https://shizune.co/investors/profile/atlas-venture) — VC Fund, 1 deal together
- [Carnegie Asset Management](https://shizune.co/investors/profile/carnegie-asset-management) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Heidelberg Innovation invest in?

Heidelberg Innovation invests primarily in Biotechnology, Pharmaceutical and Medical startups, most often at Series B and Funding Round stage. Most of the 4 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Heidelberg Innovation last invest?

The most recent investment recorded for Heidelberg Innovation closed in May 2014. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co